Abstract

Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment

Author(s): M.X. Zhang1,2, W. Tan1, R.X. Zhang3, Y.L. Tian1, H.M. Gao1,2, Z. Gao1, N. Zhang1, J.Q. Zhao1, Y.F. Jia1,2 and Y.S. Wang1,2

The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. The first patient was alive at 8 years with alternative conventional chemotherapy and gefitinib, and the second patient was alive at long-term follow-up with conventional chemotherapy and gefitinib or erlotinib. Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC.

• PDF